医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Quintiles Officially Opens Greater China Regional Headquarters in Shanghai

2015年05月29日 PM03:00
このエントリーをはてなブックマークに追加


 

SHANGHAI

More than 30 leaders from China’s government and healthcare communities joined Quintiles executives here today in officially opening the Quintiles Greater China Regional Headquarters, further expanding its ability to help Chinese companies expand globally and multinational companies succeed in the world’s second largest biopharmaceutical market. The event comes 17 years after Quintiles first opened an office in Shanghai.

“Today we celebrate not only Quintiles’ growth, but also Greater China’s emergence as a global player in biopharma R&D,” said Quintiles founder and Executive Chairman Dennis Gillings, CBE, Ph.D., at the opening ceremony at Shanghai’s Feng Lin Science Park. “Two decades ago we opened in Shanghai with 20 employees across Greater China – now we have more than 1,000. Today I’m more confident than ever that the vision shared by the leaders gathered here – of Shanghai and Greater China being centers of global innovation in biopharma R&D and healthcare – will be realized.”

Vice District Mayor Wang Hongzhou of Xihui District, Shanghai, joined Dr. Gillings in speaking at the opening.

“Quintiles is a long and valued friend and advisor to China in matters across the healthcare spectrum,” Mayor Wang said. “The Feng Lin Science Park is the centerpiece of our efforts to bring together academic and industry leaders in a central location where innovation and collaboration can thrive. We look forward to our continued partnership with Quintiles as we strive to integrate science, technology and healthcare to save lives and alleviate suffering.”

Quintiles’ 4,000-square-meter (43,000 square feet) headquarters in Shanghai’s Feng Lin Science Park now has almost 300 employees and is designed to host 450.

Ling Zhen, Quintiles general manager of Greater China, said: “Many of Greater China’s home-grown biopharma companies are looking to expand globally. Our investment is designed to help them develop their innovative pipelines with global market access in mind, opening the large markets of Japan, U.S. and Europe to their products. At the same time we’re increasing our capabilities to help multinational companies expand in Greater China.”

Quintiles Greater China has employees in almost 30 cities and offices in Beijing, Shanghai, Dalian, Hong Kong and Taipei, allowing it to serve all major population centers and study sites.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-75 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005050/en/

CONTACT

Quintiles
Jay Johnson, +65.9655.6635
Media Relations, (jay.johnson@quintiles.com)
or
Todd
Kasper, +1.919.998.2590
Investor Relations, (InvestorRelations@quintiles.com)

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表